New malaria vaccine faces first Real-World test in tanzania
NCT ID NCT07124156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test the SUM-101 malaria vaccine in 24 healthy adults in Tanzania who have been exposed to malaria before. Participants will receive three doses of the vaccine or a rabies control shot, then be deliberately infected with a controlled dose of malaria parasites to see if the vaccine delays or prevents infection. The main goal is to check safety and whether the vaccine triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SUM-101 (MSP1 protein with GLA-SE adjuvant)
What this could lead to
If it works, this could point toward a vaccine that protects against malaria by targeting the blood stage of the parasite.
What could go wrong
This is a very early Phase 1b trial with only 24 participants. Previous trials showed no efficacy data, so the vaccine may not protect against infection. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••